BTK(C481S)-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia

PURPOSE: Therapeutic targeting of Bruton tyrosine kinase (BTK) with ibrutinib in chronic lymphocytic leukemia has led to a paradigm shift in therapy, and relapse has been uncommon with current follow-up. Acquired mutations in BTK and PLCG2 can cause relapse, but data regarding the prevalence and nat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Woyach, Jennifer A., Ruppert, Amy S., Guinn, Daphne, Lehman, Amy, Blachly, James S., Lozanski, Arletta, Heerema, Nyla A., Zhao, Weiqiang, Coleman, Joshua, Jones, Daniel, Abruzzo, Lynne, Gordon, Amber, Mantel, Rose, Smith, Lisa L., McWhorter, Samantha, Davis, Melanie, Doong, Tzyy-Jye, Ny, Fan, Lucas, Margaret, Chase, Weihong, Jones, Jeffrey A., Flynn, Joseph M., Maddocks, Kami, Rogers, Kerry, Jaglowski, Samantha, Andritsos, Leslie A., Awan, Farrukh T., Blum, Kristie A., Grever, Michael R., Lozanski, Gerard, Johnson, Amy J., Byrd, John C.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2017
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5455463/
https://ncbi.nlm.nih.gov/pubmed/28418267
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.70.2282
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados